natgillin/translations-raw huggingface dataset:
RoActemra versus adalimumab i monoterapi 
RoActemra versus adalimumab in monotherapy
Sikkerhedsprofilen er udarbejdet fra 4510 patienter eksponeret for RoActemra i kliniske studier; størstedelen af disse patienter deltog i reumatoid artrit-studier (n = 4009) med voksne patienter, mens de resterende erfaringer stammer fra GCA (n = 149), pJIA (n = 240) samt sJIA (n = 112) studier. 
The safety profile comes from 4510 patients exposed to RoActemra in clinical trials; the majority of these patients were participating in adult RA studies (n=4009), while the remaining experience comes from GCA (n=149), pJIA (n=240) and sJIA (n=112) studies.
• Fremstilling af injektionen/infusionen 
• Preparation of injection/infusion
Patienterne havde gennemsnitlig DAS28 ved baseline på 6,7 i den subkutane arm og 6,6 i placebo armen. 
Patients had mean DAS28 at baseline of 6.7 on subcutaneous and 6.6 on placebo arms.
De indberettede alvorlige infektioner, nogle med dødeligt udfald, omfattede aktiv tuberkulose, som kan vise sig ved intrapulmonal eller ekstrapulmonal sygdom, invasive pulmonale infektioner, inklusive candidiasis, aspergillose, kokcidioidomykose og pneumocystis jirovecii, pneumoni, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis og bakteriel arthritis. 
Reported serious infections, some with fatal outcome, included active tuberculosis, which may present with intrapulmonary or extrapulmonary disease, invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii, pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.
• Tag æsken med fyldte penne ud af køleskabet. 
• Take the box containing the pre-filled pen out of the refrigerator.
De fleste patienter i den populationsfarmakokinetiske analyse havde normal eller let nedsat nyrefunktion. 
Most of the patients in the population pharmacokinetic analysis had normal renal function or mild renal impairment.
• Fjern ikke kanylens hætte før Trin 5. 
• Do not remove the needle-cap on your syringe until Step 5.
48,1% (39/81) af de placebobehandlede patienter oplevede flare sammenlignet med 25,6% (21/82) af de tocilizumab-behandlede patienter. 
Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients.
Virkningen af RoActemra til behandling af cytokinfrigivelsessyndrom blev undersøgt i en retrospektiv analyse af data fra kliniske forsøg med CAR T-celle behandling (tisagenlecleucel og axicabtagen ciloleucel) anvendt ved hæmatologiske maligniteter. 
The efficacy of RoActemra for the treatment of CRS was assessed in a retrospective analysis of data from clinical trials of CAR T-cell therapies (tisagenlecleucel and axicabtagene ciloleucel) for hematological malignancies.
Alle patienter, der behandles med RoActemra, skal have udleveret et patientkort.Patientens egnethed til subkutan selvadministration bør vurderes og patienten bør instrueres i at kontakte sundhedspersonalet, hvis der opleves symptomer på allergisk reaktion. 
All patients treated with RoActemra should be given the Patient Alert Card. Suitability of the patient for subcutaneous home use should be assessed and patients should be instructed to inform a healthcare professional if they experience symptoms of an allergic reaction before administering the next dose.
Effektresultater for studie VII (WA19926) hos MTX-naive patienter med tidlig reumatoid artrit 
Table 6: Efficacy Results for Study VII (WA19926) on MTX-naïve, early RA patients
• Læg den brugte RoActemra-pen og den grønne hætte i kanylebeholderen straks efter brug (se figur M). 
• Put your used RoACTEMRA pre-filled pen and green cap in a sharps disposal container right away after use (See Figure M).
Pennen må ikke rystes. 
The pen should not be shaken.
Den normale dosis RoActemra er 8 mg pr. kg kropsvægt, hvis du vejer 30 kg eller mere. 
The usual dose of RoActemra is 8 mg for every kg of body weight if you weigh 30 kg or more.
I et randomiseret, åbent studie responderede voksne RA-patienter, som var i behandling med RoActemra og MTX, effektivt på både 23-valent pneumokokpolysaccharidog tetanustoxoid-vaccine; responset var sammenligneligt med responset hos patienter, som kun var i behandling med MTX. 
In a randomized open-label study, adult RA patients treated with RoActemra and MTX were able to mount an effective response to both the 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines which was comparable to the response seen in patients on MTX only.
Spørg sundhedspersonalet om vejledning i hvordan du kommer af med brugte injektionssprøjter. 
Check with your healthcare provider for instructions about the right way to throw away used syringes.
I starten vil lægen eller sygeplejersken måske give indsprøjtningen med RoActemra. 
At the start, your doctor or nurse may inject RoActemra.
Behandling med RoActemra kan, særligt hvis det administreres samtidigt med MTX, være forbundet med stigninger i leveraminotransferase, og der bør derfor udvises forsigtighed når det overvejes at behandle patienter med aktiv leversygdom eller nedsat leverfunktion (se pkt. 
Treatment with RoActemra, particularly when administered concomitantly with MTX, may be associated with elevations in hepatic transaminases, therefore, caution should be exercised when considering treatment of patients with active hepatic disease or hepatic impairment (see sections 4.2 and 4.8).
Studie IV undersøgte 1.220 patienter, som havde responderet klinisk utilstrækkeligt på deres hidtidige reumatologiske behandling, herunder en eller flere DMARDs. 
Study IV evaluated 1,220 patients who had an inadequate response to their existing rheumatologic therapy, including one or more DMARDs.
En patient eller forældre/værge kan foretage selvadministration i de tilfælde, hvor lægen finder det hensigtsmæssigt og hvor patienten eller forældre/værge forinden er trænet i korrekt injektionsteknik efter behov samt har givet samtykke til medicinsk opfølgning. 
A patient or parent/guardian can self-inject RoActemra only if the physician determines that it is appropriate and the patient or parent/guardian agrees to medical follow-up as necessary and has been trained in proper injection technique.
Erosions-score JSN-score 
Total Sharp-Genant score Erosion score JSN score
I den kontrollerede 12 ugers fase oplevede 16 % af patienterne i tocilizumab-gruppen og 5,4 % af patienterne i placebogruppen en bivirkning inden for 24 timer efter infusionen. 
In the 12 week controlled phase, 16% of patients in the tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion.
Ved uge 24 var der observeret signifikant reduktion i DAS28 fra baseline på 3,1 observeret i den subkutane arm og 1,7 i placebo armen og for DAS28<2,6 blev der observeret en reduktion på 32,0% i den subkutane arm og en reduktion på 4,0% i placebo armen. 
At week 24, a significant reduction in DAS28 from baseline of 3.1 was observed on subcutaneous and 1.7 on placebo arm, and for DAS28 < 2.6, 32.0% was observed on subcutaneous and 4.0% on placebo arm.
Efter uge 52 kunne alle patienterne få åben behandling med RoActemra 8 mg/kg. 
After week 52, all patients could receive open-label treatment with RoActemra 8 mg/kg.
50 ud af 75 (67 %) patienter behandlet med tocilizumab havde hæmoglobin < nedre normalgrænse ved baseline. 
Fifty out of seventy five (67%) tocilizumab treated patients had a haemoglobin < LLN at baseline.
Symptomerne kan være mavesmerter og uforklarlige ændringer i afføringsmønster med feber. 
Symptoms would include abdominal pain and unexplained changes in bowel habits with a fever.
Alt indholdet (0,9 ml) i den fyldte pen skal administreres som subkutan injektion. 
The total content (0.9 mL) of the pre-filled pen should be administered as a subcutaneous injection.
RoActemra bør ikke anvendes sammen med andre biologiske midler. 
RoActemra is not recommended for use with other biological agents.
Når lægemidlet er godkendt, er indberetning af formodede bivirkninger vigtig. 
Reporting suspected adverse reactions after authorization of the medicinal product is important.
Hvis du glemmer en dosis RoActemra 
If you miss a dose of RoActemra
RoActemra monoterapi skal ikke anvendes til behandling af akutte tilbagefald, da effekten i denne kliniske sutuation ikke er blevet klarlagt. 
RoActemra monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established.
Gør indsprøjtningsstedet klar 
Prepare the Injection Site
De foreliggende data for anvendelse af tocilizumab til gravide er utilstrækkelige. 
There are no adequate data from the use of tocilizumab in pregnant women.
Prækliniske data viser ingen speciel risiko for mennesker vurderet ud fra konventionelle studier af sikkerhedsfarmakologi, toksicitet efter gentagne doser og genotoksicitet. 
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
En højere forekomst af infektioner og parasitære sygdomme blev rapporteret i RoActemra-armen (48 % vs. 42 %), men uden forskel i forekomsten af alvorlige infektioner (3, 1 %). 
A higher incidence of infections and infestations was reported in the RoActemra arm (48% vs. 42%), with no difference in the incidence of serious infections (3.1%).
Hvis en anafylaktisk reaktion eller anden alvorlig overfølsomhedsreaktion/alvorlig infusionsreaktion indtræffer, skal administrationen af RoActemra stoppes øjeblikkeligt og RoActemra bør seponeres permanent. 
If an anaphylactic reaction or other serious hypersensitivity / serious infusion related reaction occurs, administration of RoActemra should be stopped immediately and RoActemra should be permanently discontinued.
Alder, køn og etnicitet: Populationsfarmakokinetiske analyser af patienter med RA og GCA viste, at alder, køn og race ikke påvirkede RoActemras farmakokinetik. 
Age, gender and ethnicity: Population pharmacokinetic analyses in RA and GCA patients, showed that age, gender and ethnic origin did not affect the pharmacokinetics of RoActemra.
I populationen, som blev eksponeret i lang tid, var den samlede hyppighed af alvorlige infektioner (bakterie-, virus-, svampe-) 4,7 hændelser pr. 100 patientår. 
In the long-term exposure population, the overall rate of serious infections (bacterial, viral and fungal) was 4.7 events per 100 patient years.
De anbefalede injektionssteder (mave, lår og overarm) skal anvendes på skift, og injektionen må aldrig gives i skønhedspletter, ar, blå mærker eller områder, hvor huden er øm, rød, hård eller, hvor huden ikke er intakt. 
The recommended injection sites (abdomen, thigh and upper arm) should be rotated and injections should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.
Patienter, der var randomiseret til tocilizumab, havde færre ACR30-flare-episoder og et højere samlet ACR-respons end patienter, som fik placebo. 
Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use.
Det bør normalt ikke være længere end 24 timer ved 2 - 8 °C, medmindre fortyndingen fandt sted under kontrollerede og validerede aseptiske betingelser. 
If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C-8°C, unless dilution has taken place in controlled and validated aseptic conditions.
INFORMATION I BRAILLESKRIFT roactemra 162 mg pen 
INFORMATION IN BRAILLE roactemra 162 mg pen
INFORMATION I BRAILLESKRIFT Fritaget for krav om blindskrift 
INFORMATION IN BRAILLE Justification for not including Braille accepted
Injektionssprøjten er lukket med et hårdt beskyttelseshylster (elastomerforsegling med polypropylskal) og stempel (fluororesindbelagt butylgummi). 
The syringe is closed by a rigid needle shield (elastomer seal with a polypropylene shell) and a plunger stopper (butyl rubber with a fluororesin coating).
Den anbefalede dosis er 8 mg/kg legemsvægt administreret én gang hver 4. uge. 
The recommended posology is 8 mg/kg body weight, given once every four weeks.
Alle patienter, der behandles med RoActemra, skal have udleveret et patientkort. 
All patients treated with RoActemra should be given the Patient Alert Card.
• nåleskjoldet ikke er kommet ud. 
• The needle-shield may not have locked.
INFORMATION I BRAILLESKRIFT roactemra 162 mg 
INFORMATION IN BRAILLE roactemra 162 mg
Infusionsreaktioner hos pJIA-patienter defineres som alle bivirkninger, der indtræffer under eller inden for 24 timer efter en infusion. 
In pJIA patients, infusion related reactions are defined as all events occurring during or within 24 hours of an infusion.
In vitro-studier med dyrkede humane hepatocytter har vist, at IL-6 forårsager et fald i CYP1A2, CYP2C9, CYP2C19 og CYP3A4 enzym-ekspression. 
In vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19 and CYP3A4 enzyme expression.
Ingen reaktion ved injektionsstedet blev rapporteret som en alvorlig bivirkning eller, som krævede seponering af behandlingen. 
No injection site reaction was reported as a serious adverse event or required treatment discontinuation.
atorvastatin, calciumantagonister, theophyllin, warfarin, phenprocoumon, phenytoin, ciclosporin eller benzodiazepiner) kontrolleres, da dosis måske skal justeres for at bevare den terapeutiske virkning. 
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses may need to be increased to maintain therapeutic effect.
Disse resultater er i overensstemmelse med det, der ses hos patienter behandlet med intravenøs RoActemra. 
These results are consistent with those observed in patients treated with intravenous RoActemra.
Laboratorie abnormiteter 
Laboratory Abnormalities
JIA ACR-responsrater ved uge 12 (% patienter) 
JIA ACR response rates at week 12 (% patients)
Tocilizumabs sikkerhedsprofil i den pædiatriske population med pJIA- og sJIA er beskrevet i nedenstående sektioner. 
The safety profile of tocilizumab in the pediatric population is summarized in the sections on pJIA and sJIA below.
Reaktionerne blev generelt observeret under den anden til femte infusion af RoActemra (se pkt. 
These reactions were generally observed during the second to fifth infusions of RoActemra (see section 4.4).
• mavesmerter/-ømhed og/eller ændret afføringsmønster 
• abdominal pain/tenderness and/or change in bowel function
I den dobbeltblindede kontrollerede 12 ugers fase fik 75 patienter tocilizumab (8 mg/kg eller 12 mg/kg afhængigt af legemsvægt). 
In the 12 week double-blind, controlled phase, 75 patients received treatment with tocilizumab (8 mg/kg or 12 mg/kg based upon body weight).
Primært endepunkt - gennemsnitlig ændring fra baseline til uge 24 DAS28 (justeret gennemsnit) Forskel i justeret gennemsnit (95% konfidensinterval) Sekundære endepunkter - procent respondenter ved uge 24 
Primary Endpoint - Mean Change from baseline at Week 24 DAS28 (adjusted mean) Difference in adjusted mean (95% CI) Secondary Endpoints - Percentage of Responders at Week 24
• 1 kanylebeholder til sikker bortskaffelse af brugte penne og hætter til penne (se Trin 4 
• 1 Puncture-resistant container or sharps container for safe disposal of pre-filled pen cap and used pre-filled pen (see Step 4 “Dispose of the pre-filled pen”)
Ingen af patienterne behandlet med subkutan RoActemra oplevede et fald i trombocytter til ≤ 50 × 103/μl. 
No patients treated with SC RoActemra experienced a decrease in platelet count to ≤50 × 103 / μL.
En median på 1 dosis (i et spænd på 1-4 doser) af tocilizumab blev givet. 
A median of 1 dose of tocilizumab (range, 1-4 doses) was administered.
AUC, Cmin og Cmax for RoActemra steg med øget legemsvægt. 
RoActemra AUC, Cmin and Cmax increased with increase of body weight.
Den overordnede sikkerhedsprofil observeret i RoActemra behandlingsgrupperne var i overensstemmelse med den allerede kendte sikkerhedsprofil for RoActemra (se tabel 1). 
The overall safety profile observed in the RoActemra treatment groups was consistent with the known safety profile of RoActemra (see Table 1).
RoActemra er, i kombination med methotrexat (MTX), indiceret til 
RoActemra, in combination with methotrexate (MTX), is indicated for
Meget sjældne bivirkninger: Forekommer hos op til 1 ud af 10.000 patienter 
Very rare side effects: These may affect up to 1 in every 10,000 patients
Den justerede gennemsnitlige ændring på den visuelle analog skala (VAS) for smerte efter 12 ugers tocilizumab-behandling var en reduktion på 41 point på en skala fra 0 til 100 sammenlignet med en reduktion på 1 for placebo-patienter (p < 0,0001). 
The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 - 100 compared to a reduction of 1 for placebo patients (p<0.0001).
I SC-II-studiet var ACR20 på 60,9%, ACR50 på 39,8% og ACR70 på 19,7% ved uge 24 hos patienter, som var behandlet med subkutan RoActemra hver anden uge, sammenlignet med placebo, hvor ACR20 var på 31,5%, ACR50 på 12,3% og ACR70 på 5,0%. 
In study SC-II, at week 24 there was ACR20 of 60.9%, ACR50 of 39.8% and ACR70 of 19.7% for patients treated with RoActemra subcutaneous every other week versus placebo ACR20 of 31.5%, ACR50 of 12.3% and ACR70 of 5.0%.
RoActemra gives normalt sammen med methotrexat. 
RoActemra is usually given in combination with methotrexate.
Populationen, alle kontroller, omfatter alle patienter fra den dobbeltblindede fase af hvert studie fra randomeisering til enten første ændring i behandlingsregimet eller til en behandlingsvarighed på 2 år er nået. 
The all control population includes all patients from the double-blind phases of each core study from randomization until either the first change in the treatment regimen, or two years is reached.
De foreliggende data for anvendelse af RoActemra til gravide er utilstrækkelige. 
There are no adequate data from the use of RoActemra in pregnant women.
L-histidin, L-histidinmonohydrochloridmonohydrat, L-arginin, L-argininhydrochlorid, Lmethionin, polysorbat 80, vand til injektionsvæsker. 
L-Histidine, L-Histidine monohydrochloride monohydrate, L-Arginine, L-Arginine hydrochloride, LMethionine, Polysorbate 80, Water for injections.
I den kontrollerede 12 ugers fase oplevede 4 % af patienterne i tocilizumab-gruppen bivirkninger under infusion. 
In the 12 week controlled phase, 4% of patients from the tocilizumab group experienced events occurring during infusion.
Tocilizumab er et rekombinant humaniseret, anti-humant monoklonalt antistof af immunglobulin G1 (IgG1) sub-klassen rettet mod opløselige og membranbundne interleukin 6-receptorer. 
Tocilizumab is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1 (IgG1) sub-class directed against soluble and membrane-bound interleukin 6 receptors.
Du må ikke vifte eller puste på det rensede område tørt. 
Do not fan or blow on the clean area.
Fem patienter (0,8%) udviklede positive anti-RoActemra-antistoffer; af disse udviklede alle neutraliserende anti-RoActemraantistoffer. 
Five patients (0.8%) developed positive anti-RoActemra antibodies; of these, all developed neutralizing anti-RoActemra antibodies.
Let nedsat nyrefunktion (estimeret creatininclearance Baseret på Cockcroft-Gault formlen) påvirkede ikke RoActemras farmakokinetik. 
Mild renal impairment (estimated creatinine clearance based on Cockcroft-Gault formula) did not impact the pharmacokinetics of RoActemra.
Ved uge 24 sås hæmning af strukturel skade med signifikant mindre radiografisk progression blandt patienter behandlet med subkutan RoActemra sammenlignet med placebo (gennemsnitlig mTSS på 0,62 vs. 1,23; p=0,0149 (van Elteren)). 
At week 24, inhibition of structural damage was shown, with significantly less radiographic progression in patients receiving RoActemra subcutaneous compared to placebo (mean mTSS of 0.62 vs. 1.23, p=0.0149 (van Elteren).
Koncentratet er en klar til opaliserende, farveløs til lysegul væske. 
The concentrate is a clear to opalescent, colourless to pale yellow liquid.
Den fyldte pen må ikke rystes. 
The pre-filled pen should not be shaken.
En højere forekomst af infektioner og parasitære sygdomme blev rapporteret i tocilizumab-armen (48 % vs. 42 %), men uden forskel i forekomsten af alvorlige infektioner (3, 1 %). 
A higher incidence of infections and infestations was reported in the tocilizumab arm (48% vs. 42%), with no difference in the incidence of serious infections (3.1%).
Som det er anbefalet for andre biologiske behandlinger, skal alle patienter undersøges for latent tuberkulose, før behandlingen med RoActemra påbegyndes. 
As recommended for other biological treatments, all patients should be screened for latent tuberculosis (TB) infection prior to starting RoActemra therapy.
162 mg ugentligt 
162 mg weekly
Sikkerhedsprofilen for subkutan RoActemra er blevet undersøgt hos 51 pædiatriske patienter (1-17 år) med sJIA. 
The safety profile of subcutaneous RoActemra was evaluated in 51 paediatric patients (1 to 17 years of age) with sJIA.
Lægemiddelinduceret leverskade, hepatitis, gulsot. 
Drug-induced liver injury, Hepatitis, Jaundice,
Ved at blokere disse processer, kan betændelsen (inflammationen) i kroppen nedsættes. 
This protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body.
Hypertriglycerid æmi 
Hypertriglyceridae mia
Sikkerhedsprofilen af intravenøs RoActerma ved sJIA er blevet undersøgt hos 112 patienter i alderen 2 til 17 år. 
The safety profile of intravenous RoActemra in sJIA has been studied in 112 patients from 2 to 17 years of age.
RoActemra gives normalt sammen med et andet lægemiddel for leddegigt, som kaldes methotrexat. 
RoActemra is usually given in combination with another medicine for RA called methotrexate.
Påbegynd behandlingen igen ugentligt eller hver anden uge efter et klinisk skøn 
Restart with weekly or every other week injection, as clinically appropriate.
Efter subkutan dosering hos GCA-patienter var halveringstiden t½ for absorptionen på omkring 4 dage. 
Following subcutaneous dosing in GCA patients, the absorption t½ was around 4 days.
Det primære endepunkt ved uge 24 var andelen af patienter, som opnåede et ACR 20-respons. 
The primary endpoint at week 24 was the proportion of patients who achieved an ACR 20 response.
Brug ikke lægemidlet efter den udløbsdato, som står på den ydre karton. 
Do not use this medicine after the expiry date which is stated on the carton.
I alt 2.876 patienter er blevet testet for anti-tocilizumab-antistoffer i de 6-måneders kontrollerede kliniske studier. 
A total of 2,876 patients have been tested for anti-tocilizumab antibodies in the 6-month controlled clinical trials.
Ingen dosisjustering er nødvendig hos patienter med let eller moderat nedsat nyrefunktion. 
No dose adjustment is required in patients with mild or moderate renal impairment.
Patienter med reumatoid artrit har øget risiko for kardiovaskulære sygdomme, og risikofaktorer (f.eks. hypertension og hyperlipidæmi) skal behandles efter gældende standarder. 
RA patients have an increased risk for cardiovascular disorders and should have risk factors (e.g. hypertension, hyperlipidaemia) managed as part of usual standard of care.
• Du må ikke varme den fyldte pen hurtigere op, fx i mikroovn eller ved at lægge den i varmt vand. 
• Do not speed up the warming process in any way, such as using the microwave or placing the pre-filled pen in warm water.
Rør ikke ved nåleskjoldet på pennen, da du kan komme til at stikke dig selv. 
Do not touch the needle-shield of the prefilled pen, because you may stick yourself with the needle.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) RoActemra 162 mg injektion 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION RoActemra 162 mg injection
Tocilizumab versus adalimumab i monoterapi 
Tocilizumab versus adalimumab in monotherapy
Lægen kan dog vurdere, at du selv kan tage indsprøjtningen med RoActemra. 
However, your doctor may decide that you may inject RoActemra yourself.